Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
Samra Turajlic(Royal Marsden NHS Foundation Trust), Charles Swanton(The Francis Crick Institute), Ben Challacombe(Guy's and St Thomas' NHS Foundation Trust), Lavinia Spain(Royal Marsden NHS Foundation Trust), Kevin Litchfield(Cancer Research UK), Faiz Jabbar(The Francis Crick Institute), Sophia Ward(The Francis Crick Institute), Aengus Stewart(University of the Basque Country), James J. Hsieh(Memorial Sloan Kettering Cancer Center), Lisa Pickering(Royal Marsden Hospital), Emma Nye(The Francis Crick Institute), Renzo G. DiNatale(Memorial Sloan Kettering Cancer Center), Gordon Stamp(Royal Marsden Hospital), Carol Jones(Roche (United States)), Mary Falzon, George F. Mayhew(University of Wisconsin–Madison), José I. López(BioCruces Health research Institute), Thomas B.K. Watkins(The Francis Crick Institute), Mariam Jamal‐Hanjani(CRUK Lung Cancer Centre of Excellence), Daniel L. Burgess, Joanna Lynch(Royal Marsden NHS Foundation Trust), Andrew Rowan(Cancer Institute (WIA)), Nelson R. Alexander(Ventana Research Corporation (United States)), Ashish Chandra(Guy's Hospital), Lewis Au(Royal Marsden NHS Foundation Trust), Todd Richmond(Computational Physics (United States)), Sharanpreet Lall(CRUK Lung Cancer Centre of Excellence), Samantha M. Hill(University of Arizona), Aspasia Soultati, James Larkin(Trinity College Dublin), Tim Chambers(University of Canterbury), Heidi Rosenbaum, Catherine D. McNally(Ventana Research Corporation (United States)), Mark Stares(Edinburgh Cancer Research), Ed Reznik(Icahn School of Medicine at Mount Sinai), Rosa Guarch(Complejo Hospitalario de Navarra), Claudia Eichler-Jonsson(The Francis Crick Institute), Ian Proctor, Hang Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Stacey Stanislaw(Roche (United States)), David Nicol(Royal Stoke University Hospital), Sarah Rudman(Guy's and St Thomas' NHS Foundation Trust), Archana Fernando(Guy's and St Thomas' NHS Foundation Trust), Simon Chowdhury(Sarah Cannon Research Institute), Tim O’Brien(St Thomas' Hospital), Maria F. Becerra(Memorial Sloan Kettering Cancer Center), Stuart Horswell(The Francis Crick Institute), Martin Gore(Imperial College London), Steve Hazell(Royal Marsden NHS Foundation Trust)
Cited by 883
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k